Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04606446 · ClinicalTrials.gov registry record · Phase 1

Study of PF-07248144 in Advanced or Metastatic Solid Tumors

A Phase 1 study of Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Locally Advanced or Metastatic ER+ HER2- Breast Cancer, sponsored by Pfizer.

Recruiting
Registry status
Phase 1
Development phase
320
Enrollment target
20
Study locations

NCT04606446: Recruiting Phase 1 study of Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Locally Advanced or Metastatic ER+ HER2- Breast Cancer, sponsored by Pfizer.

NCT04606446 is a Phase 1 study of Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Locally Advanced or Metastatic ER+ HER2- Breast Cancer that is actively recruiting participants, run by Pfizer. The registered enrollment target is 320 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (433% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04606446, a Phase 1 study of Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Locally Advanced or Metastatic ER+ HER2- Breast Cancer, is actively recruiting participants, sponsored by Pfizer.

RECRUITING
Registry status
Phase 1
Development phase
320 participants
Enrollment target
20
Study locations

Study Summary

This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of PF-07248144 as a single agent and in combination with other agents

Primary Outcome

Dose-limiting toxicities (DLTs)

Conditions Studied

Locally Advanced or Metastatic Non-Small Cell Lung Cancer Locally Advanced or Metastatic ER+ HER2- Breast Cancer Locally Advanced or Metastatic Castration-resistant Prostate Cancer

Interventions

  • DRUG Letrozole
  • DRUG Fulvestrant
  • DRUG Palbociclib
  • DRUG PF-07220060
  • DRUG PF-07248144

Study Locations (20)

Tennessee

  • Tennessee Oncology PLLC - Franklin
  • Sarah Cannon Research Institute - Nashville
  • Tennessee Oncology PLLC - Nashville
  • The Sarah Cannon Research Institute / Tennessee Oncology, PLLC - Nashville

California

  • Cedars Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute - Los Angeles
  • Cedars-Sinai Medical Center; SOCCI Pharmacy - Los Angeles
  • UCSF Medical Center at Mission Bay - San Francisco

Connecticut

  • Smilow Cancer Hospital at Yale - New Haven - New Haven
  • Yale-New Haven Hospital- Yale Cancer Center - New Haven
  • Smilow Cancer Hospital Phase 1 Unit - New Haven

Kentucky

  • St. Elizabeth Healthcare - Edgewood
  • James Graham Brown Cancer Center - Louisville
  • University Medical Center, lnc.:DBA University of Louisville Hospital - Louisville

Texas

  • The University of Texas M. D. Anderson Cancer Center - Houston
  • U.T. MD Anderson Cancer Center - Houston
  • NEXT Oncology - San Antonio

Washington

  • Swedish Cancer Institute - Seattle
  • Swedish Medical Center - Seattle

Arizona

  • HonorHealth - Scottsdale

Florida

  • Holy Cross Hospital - Fort Lauderdale

Trial Details

FieldValue
Enrollment Target 320 participants
Start Date 2020-11-16
Est. Completion 2029-09-22
Phase Phase 1
Pfizer

1,845 total trials

What NCT04606446 shows while recruiting

NCT04606446 is an interventional study that assigns participants to a tested intervention. The registered 320 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (433% higher).

The record links to 3 conditions, with Locally Advanced or Metastatic Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Letrozole is the first listed.

NCT04606446 names 20 study sites across 8 states, led by Tennessee, California, Connecticut.

Frequently Asked Questions

What is clinical trial NCT04606446 about?

NCT04606446 is a clinical study titled "Study of PF-07248144 in Advanced or Metastatic Solid Tumors". This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of PF-07248144 as a single agent and in combination with other agents

What is the current status of trial NCT04606446?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 320 participants. The study started on 2020-11-16. Estimated completion is 2029-09-22.

What conditions does trial NCT04606446 study?

This clinical trial studies the following conditions: Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer.

What interventions are being tested in trial NCT04606446?

The interventions under investigation include: Letrozole (DRUG), Fulvestrant (DRUG), Palbociclib (DRUG), PF-07220060 (DRUG), PF-07248144 (DRUG).

Who is sponsoring clinical trial NCT04606446?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04606446 being conducted?

This trial has 20 study locations across Arizona, California, Connecticut, Florida, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04606446's enrollment target sits among peer trials

320 112th of 2000 higher than 1,886 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02763683 · 320 participants

    Investigations of Dementia in Parkinson Disease

  • NCT03331198 · 320 participants · Phase 1

    Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

  • NCT03458832 · 320 participants

    Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD

  • NCT03551951 · 320 participants

    Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT04606446

Source: ClinicalTrials.gov NCT04606446, the US trial registry maintained by the National Library of Medicine. NCT04606446 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.